In light of these newer data, patients with resected stage IIIB, IIIC, and IV melanoma could consider several options, and the panel considered anti-PD-1 antibody therapy with either nivolumab or pembrolizumab (46%), ipilimumab at 3 mg/kg (8%), D/T in BRAF mutant patients1 (13%), or high-dose interferon (4%) as acceptable recommendations. Here, BRAF is linked to melanoma.